12 Health Care Stocks Moving In Monday's Pre-Market Session
Biomea Fusion Initiated at Overweight by Capital One
Capital One Initiates Coverage On Biomea Fusion With Overweight Rating, Announces Price Target of $25
Biomea Fusion's BMF-219: A Catalyst for Growth in Metabolic Disease Treatment and Oncology
Capital One Financial Initiates Biomea Fusion(BMEA.US) With Buy Rating, Announces Target Price $25
Capital One Financial analyst Naureen Quibria initiates coverage on $Biomea Fusion(BMEA.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a success
Biomea Fusion Is Maintained at Buy by Citigroup